Company intelligence / Profile preview

S3Bio

Shenyang, Liaoning, China

Ownership: Private
Employees: ~373
Development stage: Other

Overview

3SBio is a fully integrated, profitable biotechnology company with over 30 marketed products across nephrology and oncology markets in China. The company has established market leadership, particularly with EPIAO (recombinant human erythropoietin), which has been the number one EPO product in China since 2002. Recently, 3SBio entered into a major partnership with Pfizer for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, with initial efficacy and safety data showing promise in cancer applications.[5]

Therapeutic areas: HematologyInfectious DiseasesNephrologyOncology
Modalities: Recombinant proteinBispecific monoclonal antibodyProtein
Industry: Biotech

Partnerships

Pfizer (exclusive global licensing agreement, ex-China, for SSGJ-707 development and commercialization)[5]

Beyond the preview

Go deeper on S3Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S3Bio.

Explore the full profile